Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk ...

Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

Adjuvant durvalumab did not improve disease-free survival in patients with early-stage non-small cell lung cancer in the phase 3 BR.31 trial.

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

While presenting the Union Budget for 2024-25 in the Lok Sabha, Finance Minister Nirmala Sitharaman proposed to cut customs ...

"AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...

Treatment arms included standard chemotherapy alone, chemotherapy plus programmed death ligand 1 (PD-L1) inhibitor durvalumab, and chemotherapy plus durvalumab and cytotoxic T-lymphocyte ...

NPPA asks companies to revise MRP of three anti-cancer drugs and submit information: Gireesh Babu, New Delhi Tuesday, October 29, 2024, 16:15 Hrs [IST] The National Pharmaceutical ...

The government instructed pharmaceutical companies to reduce prices on the anti-cancer drugs Trastuzumab, Osimertinib, and ...

Previous trials of neoadjuvant and adjuvant immunotherapy showed clinical benefit in this setting, and perioperative durvalumab combined with neoadjuvant gemcitabine–cisplatin (followed by ...